Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.32 USD | -0.21% | +1.39% | -28.20% |
Sales 2024 * | 611M 50.95B | Sales 2025 * | 705M 58.79B | Capitalization | 2.42B 202B |
---|---|---|---|---|---|
Net income 2024 * | 117M 9.76B | Net income 2025 * | 183M 15.27B | EV / Sales 2024 * | 3.11 x |
Net cash position 2024 * | 521M 43.43B | Net cash position 2025 * | 621M 51.79B | EV / Sales 2025 * | 2.56 x |
P/E ratio 2024 * |
22.9
x | P/E ratio 2025 * |
14.9
x | Employees | 352 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 68.25% |
Latest transcript on Corcept Therapeutics Incorporated
1 day | -0.21% | ||
1 week | +1.39% | ||
1 month | -7.42% | ||
3 months | +10.52% | ||
6 months | -16.95% | ||
Current year | -28.20% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Belanoff
FOU | Founder | 66 | 13/98/13 |
Atabak Mokari
DFI | Director of Finance/CFO | 47 | 01/21/01 |
Joseph Lyon
CTO | Chief Tech/Sci/R&D Officer | 46 | 01/12/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Belanoff
FOU | Founder | 66 | 13/98/13 |
Gregg Alton
BRD | Director/Board Member | 58 | 12/20/12 |
George Baker
BRD | Director/Board Member | 81 | 01/99/01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.71% | 29 M€ | -5.25% | ||
0.30% | 45 M€ | -1.28% | ||
0.27% | 27 M€ | -6.44% | - |
Date | Price | Change | Volume |
---|---|---|---|
30/24/30 | 23.32 | -0.21% | 1,788,923 |
29/24/29 | 23.37 | +2.50% | 556,258 |
26/24/26 | 22.8 | +2.66% | 820,551 |
25/24/25 | 22.21 | -1.20% | 1,176,227 |
24/24/24 | 22.48 | -2.26% | 1,087,749 |
Delayed Quote Nasdaq, April 01, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.20% | 2.42B | |
+34.00% | 704B | |
+26.34% | 577B | |
-7.75% | 348B | |
+18.53% | 327B | |
+4.95% | 288B | |
+15.00% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-4.89% | 147B |
- Stock Market
- Equities
- CORT Stock